Literature DB >> 17223437

Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy.

Benjamin D Mackie1, Sameer Satija, Christine Nell, Joseph Miller, Laurence S Sperling.   

Abstract

Statins are normally administered for the treatment of dyslipidemia on a daily basis. This standard dosing regimen is well tolerated by most patients. Occasionally, patients discontinue therapy secondary to side effects, most commonly myalgias. We describe 2 patients who were unable to tolerate daily atorvastatin therapy secondary to myalgias and were subsequently treated with rosuvastatin administered on Mondays, Wednesdays, and Fridays, with resolution of adverse effects. Significant reductions in serum low-density lipoprotein cholesterol levels were observed in the 2 patients despite the alternate-day dosing regimen. Rosuvastatin was chosen because of its long half-life (19 hours) and very high potency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17223437     DOI: 10.1016/j.amjcard.2006.07.093

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Rhabdomyolysis caused by an interaction of simvastatin and fusidic acid.

Authors:  Roselle Herring; Gordon Caldwell; Stuart Wade
Journal:  BMJ Case Rep       Date:  2009-09-20

2.  Alternate day dosing of rosuvastatin: potential usefulness in statin-intolerant patients.

Authors:  Tisha Joy; Robert A Hegele
Journal:  Can J Cardiol       Date:  2009-08       Impact factor: 5.223

3.  Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience.

Authors:  Warner M Mampuya; David Frid; Michael Rocco; Julie Huang; Danielle M Brennan; Stanley L Hazen; Leslie Cho
Journal:  Am Heart J       Date:  2013-08-05       Impact factor: 4.749

Review 4.  Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

Authors:  Yiannis S Chatzizisis; Konstantinos C Koskinas; Gesthimani Misirli; Christos Vaklavas; Apostolos Hatzitolios; George D Giannoglou
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

5.  Treating statin-intolerant patients.

Authors:  Marcello Arca; Giovanni Pigna
Journal:  Diabetes Metab Syndr Obes       Date:  2011-04-28       Impact factor: 3.168

6.  Management of statin intolerance.

Authors:  Soma B Raju; Kiron Varghese; K Madhu
Journal:  Indian J Endocrinol Metab       Date:  2013-11

7.  Periodic rosuvastatin or atorvastatin dosing arrays (PRADA): patient-centered practice.

Authors:  Theodore Christou; Hesham R Omar; Roger Dimitrov
Journal:  Drugs R D       Date:  2014-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.